Janney Montgomery Scott LLC decreased its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 49.5% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 24,122 shares of the biopharmaceutical company’s stock after selling 23,621 shares during the period. Janney Montgomery Scott LLC’s holdings in Catalyst Pharmaceuticals were worth $324,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds have also bought and sold shares of the company. BlackRock Inc. increased its position in Catalyst Pharmaceuticals by 119.6% during the third quarter. BlackRock Inc. now owns 15,268,931 shares of the biopharmaceutical company’s stock valued at $195,902,000 after acquiring an additional 8,317,115 shares during the last quarter. State Street Corp increased its position in Catalyst Pharmaceuticals by 39.0% during the third quarter. State Street Corp now owns 7,555,423 shares of the biopharmaceutical company’s stock valued at $96,936,000 after acquiring an additional 2,117,944 shares during the last quarter. Vanguard Group Inc. increased its position in Catalyst Pharmaceuticals by 26.3% during the third quarter. Vanguard Group Inc. now owns 6,139,650 shares of the biopharmaceutical company’s stock valued at $78,772,000 after acquiring an additional 1,277,662 shares during the last quarter. Millennium Management LLC boosted its stake in shares of Catalyst Pharmaceuticals by 134.1% during the second quarter. Millennium Management LLC now owns 2,723,895 shares of the biopharmaceutical company’s stock valued at $19,095,000 after purchasing an additional 1,560,086 shares during the period. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Catalyst Pharmaceuticals by 2.9% during the first quarter. Dimensional Fund Advisors LP now owns 2,374,508 shares of the biopharmaceutical company’s stock valued at $39,369,000 after purchasing an additional 65,803 shares during the period. Institutional investors own 77.27% of the company’s stock.
Wall Street Analyst Weigh In
A number of brokerages have recently issued reports on CPRX. StockNews.com began coverage on shares of Catalyst Pharmaceuticals in a research note on Thursday, October 5th. They set a “hold” rating for the company. Cantor Fitzgerald reissued an “overweight” rating and set a $27.00 target price on shares of Catalyst Pharmaceuticals in a research note on Tuesday, August 22nd. Finally, HC Wainwright reissued a “buy” rating and set a $24.00 target price on shares of Catalyst Pharmaceuticals in a research note on Friday, August 11th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $24.75.
Catalyst Pharmaceuticals Price Performance
NASDAQ:CPRX opened at $12.64 on Thursday. Catalyst Pharmaceuticals, Inc. has a 1-year low of $11.09 and a 1-year high of $22.11. The company has a 50-day moving average of $12.83 and a 200 day moving average of $13.43. The firm has a market cap of $1.35 billion, a PE ratio of 12.51 and a beta of 1.16.
Catalyst Pharmaceuticals (NASDAQ:CPRX – Get Free Report) last released its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported $0.33 earnings per share for the quarter, topping analysts’ consensus estimates of $0.25 by $0.08. The company had revenue of $99.58 million during the quarter, compared to analyst estimates of $92.77 million. Catalyst Pharmaceuticals had a net margin of 38.14% and a return on equity of 36.13%. Sell-side analysts anticipate that Catalyst Pharmaceuticals, Inc. will post 1.29 EPS for the current fiscal year.
Catalyst Pharmaceuticals Company Profile
Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.
Featured Stories
- Five stocks we like better than Catalyst Pharmaceuticals
- How to Calculate Inflation Rate
- First Solar, an affordable, high-quality green investment
- Insider Selling Explained: Can it Inform Your Investing Choices?
- 5 Dow stocks to track during the market correction
- What Does Downgrade Mean in Investing?
- Lean on these stocks during GDP expansion
Want to see what other hedge funds are holding CPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report).
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
